Baricitinib-Loaded Separable Microneedle Array Patch Based on Hyaluronic Acid for Alopecia Areata Therapy

    January 2025
    Da In Jeong, Song Yi Lee, Sungyun Kim, Seong Jin Jo, Haifeng Yang, Jae-hyuk You, ChaeRim Hwang, Ji Won Huh, Yeoung Eun Choi, W. S. Jo, In-Jeong Choi, Shunro Matsumoto, Seungki Baek, Woonsung Na, Jung‐Hwan Park, Hyun‐Jong Cho
    From the encyclopedia
    Baricitinib →

    JAK inhibitor that reduces inflammation and immune attacks on hair follicles, leading to potential hair regrowth, especially in alopecia areata cases

    Hyaluronic Acid →
    Alopecia Areata →

    autoimmune disorder causing patchy hair loss

    Image
    Studysummary In this study on mice, a baricitinib-loaded microneedle patch enhanced hair growth in alopecia areata lesions (68% vs control: 33%, p < 0.05), suggesting it may deliver treatment effectively and pain-free, with fewer systemic side effects.
    Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
    The study presents a novel separable microneedle array patch (S-MAP) based on hyaluronic acid for the topical delivery of baricitinib to treat alopecia areata (AA). This method aims to avoid the systemic side effects of oral administration and offers a pain-free alternative to typical intradermal injections. The baricitinib-loaded S-MAP demonstrated effective insertion in porcine and mouse skin, with significantly higher hair growth in mouse models compared to the control group (68% vs 33%, p < 0.05). These findings suggest that the baricitinib S-MAP system is an efficient and safe option for AA therapy, allowing for self-medication without pain.
    Discuss this study in the Community →